HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Posttreatment Lyme disease syndrome.

Abstract
The prognosis following appropriate antibiotic treatment of early or late Lyme disease is favorable but can be complicated by persistent symptoms of unknown cause termed posttreatment Lyme disease syndrome (PTLDS), characterized by fatigue, musculoskeletal pain, and cognitive complaints that persist for 6 months or longer after completion of antibiotic therapy. Risk factors include delayed diagnosis, increased severity of symptoms, and presence of neurologic symptoms at time of initial treatment. Two-tier serologic testing is neither sensitive nor specific for diagnosis of PTLDS because of variability in convalescent serologic responses after treatment of early Lyme disease. Optimal treatment of PTLDS awaits more precise understanding of the pathophysiologic mechanisms involved in this illness and future treatment trials.
AuthorsJohn N Aucott
JournalInfectious disease clinics of North America (Infect Dis Clin North Am) Vol. 29 Issue 2 Pg. 309-23 (Jun 2015) ISSN: 1557-9824 [Electronic] United States
PMID25999226 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • Cognition Disorders (etiology)
  • Fatigue (etiology)
  • Humans
  • Lyme Disease (complications, diagnosis, drug therapy)
  • Pain (etiology)
  • Prognosis
  • Quality of Life
  • Syndrome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: